

**PRESS RELEASE**

**VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY**

***In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)***

**Paris, France, August 27, 2025**

Market: Euronext Paris / Nasdaq

Euronext Compartment: B

ISIN code: FR0011341205

Nasdaq: NBTX

Bloomberg: NANO:FP

Reuters: NANO.PA

Website: [www.nanobiotix.com](http://www.nanobiotix.com)

| Date          | Number of Shares Outstanding | Total number of voting rights                 |   |
|---------------|------------------------------|---|---|
|               |                              | Total voting rights, theoretical <sup>1</sup> | Total voting rights, exercisable <sup>2</sup> |
| July 31, 2025 | 48,236,671                   | 50,340,736                                    | 50,318,618                                    |

\*\*\*

**About NANOBIOTIX**

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at [www.nanobiotix.com](http://www.nanobiotix.com) or follow us on [LinkedIn](#) and [Twitter](#).

<sup>1</sup> The total number of theoretical (or "gross") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

<sup>2</sup> The total number of exercisable at a shareholders' meeting (or "net") voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.

## Contacts

---

### *Nanobiotix*

---

#### **Communications Department**

Brandon Owens  
VP, Communications  
+1 (617) 852-4835  
[contact@nanobiotix.com](mailto:contact@nanobiotix.com)

#### **Investor Relations Department**

Joanne Choi  
VP, Investor Relations (US)  
+1 (713) 609-3150  
  
Ricky Bhajun  
Director, Investor Relations (EU)  
  
[investors@nanobiotix.com](mailto:investors@nanobiotix.com)

---

### *Media Relations*

---

France – **HARDY**  
Caroline Hardy  
+33 06 70 33 49 50  
[carolinehardy@outlook.fr](mailto:carolinehardy@outlook.fr)

Global – **uncapped**  
Becky Lauer  
+1 (646) 286-0057  
[uncappednanobiotix@uncappedcommunications.com](mailto:uncappednanobiotix@uncappedcommunications.com)

**NBTX**  
Nasdaq Listed

**NANO**  
LISTED  
EURONEXT